Literature DB >> 23398365

Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis.

Kai Chen Wang1, Chao-Lin Lee, Shao-Yuan Chen, Jeen-Chen Chen, Chih-Wen Yang, Shyi-Jou Chen, Ching-Piao Tsai.   

Abstract

Multiple sclerosis (MS) is the most common prototypic inflammatory demyelinating disease. Neuromyelitis optica (NMO) is another inflammatory demyelinating disease of the central nervous system that exhibits clinical symptoms mainly associated with optic neuritis and myelopathy. The inflammatory reaction in MS is associated with an upregulation of a variety of T helper 1 (Th1)- or Th17-mediated cytokines. However, NMO and MS are intertwined both clinically and pathologically, which complicates their diagnosis and treatment. The aim of this study was to evaluate the differences in serum cytokine levels in patients with NMO and MS. We collected peripheral serum from patients with these central nervous system demyelinating diseases for the study. A cytometric bead array was used to assess the cytokine levels using flow cytometry. We found more inflammatory [interleukin (IL)-2 and interferon-γ) and anti-inflammatory (IL-4 and IL-10) cytokines in NMO than in MS. The differences in the optimal cutoff points of serum cytokines, including IL-2 ≥5 pg/mL, can differentiate NMO from MS. In conclusion, patients with NMO had an increased Th1-mediated inflammatory response, but similar Th17-mediated inflammation changes compared to patients with MS. Serum cytokine studies can differentiate NMO cases from MS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23398365     DOI: 10.1089/jir.2012.0040

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  8 in total

1.  Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica spectrum disorder.

Authors:  A Uzawa; M Mori; H Masuda; R Ohtani; T Uchida; R Aoki; S Kuwabara
Journal:  Clin Exp Immunol       Date:  2020-07-23       Impact factor: 4.330

2.  Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation.

Authors:  Athanasia Mouzaki; Maria Rodi; Nikolaos Dimisianos; Andreas Emmanuil; Dimitra Kalavrizioti; Rosa Lagoudaki; Nikolaos C Grigoriadis; Panagiotis Papathanasopoulos
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

3.  Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes.

Authors:  Gabriel Arellano; Eric Acuña; Lilian I Reyes; Payton A Ottum; Patrizia De Sarno; Luis Villarroel; Ethel Ciampi; Reinaldo Uribe-San Martín; Claudia Cárcamo; Rodrigo Naves
Journal:  Front Immunol       Date:  2017-06-30       Impact factor: 7.561

4.  Altered humoral immunity to mycobacterial antigens in Japanese patients affected by inflammatory demyelinating diseases of the central nervous system.

Authors:  Davide Cossu; Kazumasa Yokoyama; Yuji Tomizawa; Eiichi Momotani; Nobutaka Hattori
Journal:  Sci Rep       Date:  2017-06-09       Impact factor: 4.379

5.  Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica.

Authors:  Robert Wilson; Mateusz Makuch; Anne-Kathrin Kienzler; James Varley; Jennifer Taylor; Mark Woodhall; Jacqueline Palace; M Isabel Leite; Patrick Waters; Sarosh R Irani
Journal:  Brain       Date:  2018-04-01       Impact factor: 13.501

Review 6.  A Comprehensive Review on the Role of Genetic Factors in Neuromyelitis Optica Spectrum Disorder.

Authors:  Soudeh Ghafouri-Fard; Tahereh Azimi; Mohammad Taheri
Journal:  Front Immunol       Date:  2021-10-05       Impact factor: 7.561

7.  Distinct serum apolipoprotein A-I levels in neuromyelitis optica and acute transverse myelitis.

Authors:  Yu-Hua Zhong; Jia Liu; Min Li; Xuan Wang; Yuan Yuan; Xiu-Feng Zhong; Fu-Hua Peng
Journal:  Lipids Health Dis       Date:  2013-10-23       Impact factor: 3.876

Review 8.  Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications.

Authors:  Giordani Rodrigues Dos Passos; Douglas Kazutoshi Sato; Jefferson Becker; Kazuo Fujihara
Journal:  Mediators Inflamm       Date:  2016-01-28       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.